Evommune: the decline slams the brakes
Evommune stock slips 1% as the decline stalls between two key levels
Evommune: the decline slams the brakes
Our view last week
Evommune shares slide another 6.4% this week, the fourth straight lower high from the 14 area down to the 12 area: the sequence confirms the decline is still intact. Signal strength reads "downtrend making lower lows, pace holding" — a healthy decline with no sign of exhaustion — while the short is already more than 12% in profit. In this technical analysis, volatility stands out too, running very high: the quality band flags trading as not recommended for fresh entries.
This week's summary
Evommune's decline slams the brakes: after weeks of heavy losses, this session closes at -1%, versus -6.4% seven days ago. Evommune stock stays locked in a sequence of lower highs, from the 13 area to the 12 area, but money flow is still negative and weekly volume still tilts toward sellers. The short is already above 13% in profit, on a name with very high volatility.
IQS Phase
71
in tension
Signal Strength
6
decline losing steam
Sizing
MINIMUM
Ranking
#84 / 138
US stocks
Trade P&L %
+13.19%
from signal to date, no stop loss
Rank position
ranks 84th among the 138 sell signals for US stocks in our ranking, with a signal strength of 6 out of 100.
Sector context
SectorHealth Care
Benchmark ETFXLV
Sector regimein positive regime
Performanceweekly -0.01% · monthly +1.89%
EVMN belongs to the health care sector (reference ETF XLV). The sector is classified in positive regime according to our weekly reading.
restricted Platinum content